Engineering T cell therapies for lung cancer

Engineering T cell therapies for lung cancerIn our recent publication, "c-JUN enhances CRISPR knockin anti-B7-H3 CAR T cell function in small cell lung cancer thoracic SMARCA4-deficient undifferentiated tumors," 1 we utilized a nonviral CRISPR-Cas9 knockin (CKI) platform to engineer CAR T cells targeting small cell lung cancer (SCLC) and thoracic SMARCA4-deficient undifferentiated tumors (thoracic SMARCA4-deficient UTs).Lung cancer remains the leading cause of cancer death.Viral vector production for T cell engineering poses a major bottleneck for both developing novel engineered T cells with synthetic immunoreceptors and their broad application.We posit that non-viral engineering via CKI can overcome these limitations and enable broad access to engineered T cell therapies, including CAR T cells, against lung cancer.